Anditixafortide

Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative[1]. Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

Product Specifications

CAS Number

[1821136-83-7]

UNSPSC

12352209

Target

CXCR; Radionuclide-Drug Conjugates (RDCs)

Type

Peptides

Related Pathways

Antibody-drug Conjugate/ADC Related; GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/anditixafortide.html

Purity

99.27

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C([C@@H](NC([C@H](N(C([C@H](NC(CNC1=O)=O)CC2=CC(I)=C(C=C2)O)=O)C)CCCNC(C3=CC=C(C=C3)CNC(CN4CCN(CCN(CCN(CC4)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)=O)CCCNC(N)=N)N[C@H]1CC5=CC6=C(C=CC=C6)C=C5

Molecular Formula

C60H79IN14O14

Molecular Weight

1347.26

References & Citations

[1]Nicolas Lepareur, et al. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. Pharmaceutics. 223, 15, 6.|[2]Ken Herrmann, et al. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. J Nucl Med. 2016, 57, 2.